Parkinson’s Disease Drugs Market Size, Share, Trends, Growth, and Forecasts for 2025 – 2032

Table of Content

1. Executive Summary
   1. Global Parkinson’s Disease Drugs Market Snapshot, 2025 and 2032
   2. Market Opportunity Assessment, 2025 - 2032, US$ Bn
   3. Key Market Trends
   4. Future Market Projections
   5. Premium Market Insights
   6. Industry Developments and Key Market Events
   7. PMR Analysis and Recommendations
2. Market Overview
   1. Market Scope and Definition
   2. Market Dynamics
      1. Drivers
      2. Restraints
      3. Opportunity
      4. Challenges
      5. Key Trends
   3. COVID-19 Impact Analysis
   4. Forecast Factors - Relevance and Impact
3. Value Chain Analysis
   1. Supply Chain Analysis
   2. List of Key Market Players
4. Value Added Insights
   1. PESTLE Analysis
   2. Porter’s Five Force Analysis
5. Price Trend Analysis, 2019 - 2032
   1. Pricing Analysis, By Mechanism of Action
   2. Key Factors Impacting Prices, by Route of Administration
6. Global Parkinson’s Disease Drugs Market Outlook
   1. 1. Market Size (US$ Bn) and Y-o-Y Growth
      2. Absolute $ Opportunity
   2. Market Size (US$ Bn) Analysis and Forecast
      1. Historical Market Size (US$ Bn) Analysis, 2019-2024
      2.  Market Size (US$ Bn) Analysis and Forecast, 2025-2032
   3. Global Parkinson’s Disease Drugs Market Outlook: Mechanism of Action
      1. Historical Market Size (US$ Bn) Analysis, By Mechanism of Action, 2019-2024
      2.  Market Size (US$ Bn) Analysis and Forecast, By Mechanism of Action, 2025-2032
         1. Dopamine Agonists
         2. Anticholinergics
         3. MAO-B Inhibitors
         4. Amantadine
         5. Carbidopa-Levodopa
         6. Adenosine A2A Antagonists
         7. Others
      3. Market Attractiveness Analysis: Mechanism of Action
   4. Global Parkinson’s Disease Drugs Market Outlook: Route of Administration
      1. Historical Market Size (US$ Bn) Analysis, By Route of Administration, 2019-2024
      2.  Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2025-2032
         1. Oral
         2. Transdermal
         3. Subcutaneous
         4. Intranasal
         5. Infusion
      3. Market Attractiveness Analysis: Route of Administration
   5. Global Parkinson’s Disease Drugs Market Outlook: Distribution Channel
      1. Historical Market Size (US$ Bn) Analysis, By Distribution Channel, 2019-2024
      2.  Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025-2032
         1. Hospital Pharmacies
         2. Retail Pharmacies
         3. Online Pharmacies
      3. Market Attractiveness Analysis: Distribution Channel
7. Global Parkinson’s Disease Drugs Market Outlook: Region
   1. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2024
   2.  Market Size (US$ Bn) Analysis and Forecast, By Region, 2025-2032
      1. North America
      2. Europe
      3. East Asia
      4. South Asia and Oceania
      5. Latin America
      6. Middle East & Africa
   3. Market Attractiveness Analysis: Region
8. North America Parkinson’s Disease Drugs Market Outlook
   1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
      1. By Country
      2. By Mechanism of Action
      3. By Route of Administration
      4. By Distribution Channel
   2.  Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
      1. U.S.
      2. Canada
   3.  Market Size (US$ Bn) Analysis and Forecast, By Mechanism of Action, 2025-2032
      1. Dopamine Agonists
      2. Anticholinergics
      3. MAO-B Inhibitors
      4. Amantadine
      5. Carbidopa-Levodopa
      6. Adenosine A2A Antagonists
      7. Others
   4.  Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2025-2032
      1. Oral
      2. Transdermal
      3. Subcutaneous
      4. Intranasal
      5. Infusion
   5.  Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025-2032
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
   6. Market Attractiveness Analysis
9. Europe Parkinson’s Disease Drugs Market Outlook
   1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
      1. By Country
      2. By Mechanism of Action
      3. By Route of Administration
      4. By Distribution Channel
   2.  Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
      1. Germany
      2. France
      3. U.K.
      4. Italy
      5. Spain
      6. Russia
      7. Türkiye
      8. Rest of Europe
   3.  Market Size (US$ Bn) Analysis and Forecast, By Mechanism of Action, 2025-2032
      1. Dopamine Agonists
      2. Anticholinergics
      3. MAO-B Inhibitors
      4. Amantadine
      5. Carbidopa-Levodopa
      6. Adenosine A2A Antagonists
      7. Others
   4.  Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2025-2032
      1. Oral
      2. Transdermal
      3. Subcutaneous
      4. Intranasal
      5. Infusion
   5.  Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025-2032
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
   6. Market Attractiveness Analysis
10. East Asia Parkinson’s Disease Drugs Market Outlook
    1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
       1. By Country
       2. By Mechanism of Action
       3. By Route of Administration
       4. By Distribution Channel
    2.  Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
       1. China
       2. Japan
       3. South Korea
    3.  Market Size (US$ Bn) Analysis and Forecast, By Mechanism of Action, 2025-2032
       1. Dopamine Agonists
       2. Anticholinergics
       3. MAO-B Inhibitors
       4. Amantadine
       5. Carbidopa-Levodopa
       6. Adenosine A2A Antagonists
       7. Others
    4.  Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2025-2032
       1. Oral
       2. Transdermal
       3. Subcutaneous
       4. Intranasal
       5. Infusion
    5.  Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025-2032
       1. Hospital Pharmacies
       2. Retail Pharmacies
       3. Online Pharmacies
    6. Market Attractiveness Analysis
11. South Asia & Oceania Parkinson’s Disease Drugs Market Outlook
    1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
       1. By Country
       2. By Mechanism of Action
       3. By Route of Administration
       4. By Distribution Channel
    2.  Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
       1. India
       2. Southeast Asia
       3. ANZ
       4. Rest of South Asia & Oceania
    3.  Market Size (US$ Bn) Analysis and Forecast, By Mechanism of Action, 2025-2032
       1. Dopamine Agonists
       2. Anticholinergics
       3. MAO-B Inhibitors
       4. Amantadine
       5. Carbidopa-Levodopa
       6. Adenosine A2A Antagonists
       7. Others
    4.  Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2025-2032
       1. Oral
       2. Transdermal
       3. Subcutaneous
       4. Intranasal
       5. Infusion
    5.  Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025-2032
       1. Hospital Pharmacies
       2. Retail Pharmacies
       3. Online Pharmacies
    6. Market Attractiveness Analysis
12. Latin America Parkinson’s Disease Drugs Market Outlook
    1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
       1. By Country
       2. By Mechanism of Action
       3. By Route of Administration
       4. By Distribution Channel
    2.  Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
       1. Brazil
       2. Mexico
       3. Rest of Latin America
    3.  Market Size (US$ Bn) Analysis and Forecast, By Mechanism of Action, 2025-2032
       1. Dopamine Agonists
       2. Anticholinergics
       3. MAO-B Inhibitors
       4. Amantadine
       5. Carbidopa-Levodopa
       6. Adenosine A2A Antagonists
       7. Others
    4.  Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2025-2032
       1. Oral
       2. Transdermal
       3. Subcutaneous
       4. Intranasal
       5. Infusion
    5.  Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025-2032
       1. Hospital Pharmacies
       2. Retail Pharmacies
       3. Online Pharmacies
    6. Market Attractiveness Analysis
13. Middle East & Africa Parkinson’s Disease Drugs Market Outlook
    1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
       1. By Country
       2. By Mechanism of Action
       3. By Route of Administration
       4. By Distribution Channel
    2.  Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
       1. GCC Countries
       2. Egypt
       3. South Africa
       4. Northern Africa
       5. Rest of Middle East & Africa
    3.  Market Size (US$ Bn) Analysis and Forecast, By Mechanism of Action, 2025-2032
       1. Dopamine Agonists
       2. Anticholinergics
       3. MAO-B Inhibitors
       4. Amantadine
       5. Carbidopa-Levodopa
       6. Adenosine A2A Antagonists
       7. Others
    4.  Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2025-2032
       1. Oral
       2. Transdermal
       3. Subcutaneous
       4. Intranasal
       5. Infusion
    5.  Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025-2032
       1. Hospital Pharmacies
       2. Retail Pharmacies
       3. Online Pharmacies
    6. Market Attractiveness Analysis
14. Competition Landscape
    1. Market Share Analysis, 2025
    2. Market Structure
       1. Competition Intensity Mapping By Market
       2. Competition Dashboard
    3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
       1. AbbVie Inc.
          1. Overview
          2. Segments and Mechanism of Action
          3. Key Financials
          4. Market Developments
          5. Market Strategy
       2. GSK plc
       3. Viatris Inc.
       4. Amneal Pharmaceuticals LLC
       5. Boehringer Ingelheim Intl. GmbH
       6. F. Hoffmann-La Roche Ltd.
       7. Novartis AG
       8. Pfizer Inc.
       9. Teva Pharmaceutical Industries Ltd.
       10. Sunovion Pharmaceuticals Inc.
       11. AstraZeneca
       12. ABL bio
       13. ACADIA Pharmaceuticals Inc.
       14. Prevail Therapeutics
       15. Kissei Pharmaceutical Co., Ltd.
       16. Newron Pharmaceuticals S.p.A.
       17. UCB S.A.
       18. Supernus Pharmaceuticals, Inc.
       19. Lundbeck A/S
       20. Neurocrine Biosciences, Inc.
       21. Voyager Therapeutics, Inc.
       22. Others
15. Appendix
    1. Research Methodology
    2. Research Assumptions
    3. Acronyms and Abbreviations